Lung cancer gene therapy trial halted early
Disease control
Terminated
This early-stage trial tested a new gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced non-small cell lung cancer who had already received treatment. The goal was to see if the combination was sa…
Phase: PHASE1 • Sponsor: Genprex, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC